Is this biotech an investment worth buying and holding today?
INNYes, drug R&D is difficult, costly and risky. But these factors don’t really justify a high price. Value does.
INNNew Jersey, United States - The Global Anaerobic Digestion Plants Market is carefully rese
INNThe WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
INN-- DJS Antibodies’ DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company’s proprietary HEPTAD platform will extend AbbVie’s current disco...
INN“We estimated that 1.64% of women who never used hair straighteners would go on to develop uterine cancer by the age of 70, but for frequent users, that risk goes up to 4.05%,” study leader Alexandra White of the U.S. National Institute of Environmental Health Safety (NIEHS) said in a statement. Ad…
Sioux City Catholic GlobeNew Jersey, United States - “Rare Hemophilia Factors Market Insight, Forecast 2028” is recently
Sioux City Catholic GlobeIonis Pharmaceuticals has 3 approved therapies, but operates in the red. See why I like IONS for the long run.
Sioux City Catholic GlobeIn this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expecte…
New Jersey, United States - Verified Market Research recently published a research report
Sioux City Catholic GlobeLet’s break down how Biogen makes money right now and what’s next for the company in light of some major news that surfaced recently about their new Alzheimer’s treatment.
ForbesSeniors had reason to let out a whimper of pleasure when the Biden Administration announced that Medicare’s monthly, part B premiums would go...
INNABBVie (NYSE: ABBV) and Fighting Blindness Canada have launched the Glaucoma in Perspective (GiP) app to help Canadians understand the impact of glaucoma and manage disease progression. The launch of GiP coincides with World Sight Day, as the vision loss community comes together to raise awareness..…
INNA senior researcher who was most recently at Johnson & Johnson has emerged as a top candidate to be Biogen’s CEO, according to people familiar with the discussions.
SURPERFORMANCE<p>The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera. </p>
SURPERFORMANCE| October 7, 2022
| October 7, 2022
Biogen announced that the EMA has accepted the MAA for BIIB800 (biosimilar tocilizumab). Biogen holds the rights to commercialise Bio-Thera’s product…
WHYYTwo biotech companies announced last week that preliminary trial data show their new Alzheimer’s drug, lecanemab, slowed cognitive decline.
WHYYGlobal Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic...
